Aditxt, Inc. ADTX
We take great care to ensure that the data presented and summarized in this overview for Aditxt, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in ADTX
Top Purchases
Top Sells
About ADTX
Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.
Insider Transactions at ADTX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 07
2023
|
Bnp Paribas Securities Corp |
SELL
Open market or private sale
|
Direct |
20,800
-48.21%
|
$686,400
$33.23 P/Share
|
|
Jul 19
2022
|
Amro A. Albanna Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
1
+50.0%
|
$20,000
$20000.0 P/Share
|
|
Jun 04
2021
|
Corinne Pankovcin CCO |
BUY
Grant, award, or other acquisition
|
Direct |
55,000
+24.53%
|
-
|
|
Jun 04
2021
|
Rowena Albanna Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Indirect |
75,000
+8.32%
|
-
|
|
Jun 04
2021
|
Amro A. Albanna Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+8.32%
|
-
|
|
Jun 01
2021
|
Rowena Albanna Chief Operating Officer |
BUY
Open market or private purchase
|
Indirect |
3,400
+0.09%
|
$6,800
$2.92 P/Share
|
|
Jun 01
2021
|
Amro A. Albanna Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
3,400
+0.09%
|
$6,800
$2.92 P/Share
|
|
Jun 01
2021
|
Shahrokh Shabahang Chief Innovation Officer |
BUY
Open market or private purchase
|
Indirect |
490
+0.05%
|
$980
$2.93 P/Share
|
|
Jun 01
2021
|
Jeffrey W. Runge Director |
BUY
Open market or private purchase
|
Direct |
10,000
+18.92%
|
$20,000
$2.94 P/Share
|
|
May 27
2021
|
Shahrokh Shabahang Chief Innovation Officer |
BUY
Open market or private purchase
|
Direct |
185
+0.02%
|
$370
$2.7 P/Share
|
|
May 26
2021
|
Thomas J Farley Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
2,500
+50.0%
|
$5,000
$2.68 P/Share
|
|
May 25
2021
|
Shahrokh Shabahang Chief Innovation Officer |
BUY
Open market or private purchase
|
Indirect |
417
+0.02%
|
$834
$2.39 P/Share
|
|
May 25
2021
|
Corinne Pankovcin CCO |
BUY
Open market or private purchase
|
Direct |
4,220
+3.56%
|
$8,440
$2.56 P/Share
|
|
Mar 17
2021
|
Shahrokh Shabahang Chief Innovation Officer |
BUY
Exercise of out-of-the-money derivative securities
|
Indirect |
18,750
+1.81%
|
$75,000
$4.0 P/Share
|
|
Feb 24
2021
|
Amro A. Albanna Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
225,000
+22.56%
|
-
|
|
Feb 24
2021
|
Corinne Pankovcin CCO |
BUY
Grant, award, or other acquisition
|
Direct |
110,000
+50.0%
|
-
|
|
Feb 24
2021
|
Rowena Albanna Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Indirect |
225,000
+22.56%
|
-
|
Last 12 Months Summary
| Open market or private sale | 20.8K shares |
|---|